127264-10-2

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 10 carbon (C) atoms, 11 hydrogen (H) atoms, 1 bromine (Br) atom, and 2 oxygen (O) atoms.

Explanation

The compound is derived from 1,4-benzodioxin, which is a bicyclic organic compound consisting of two fused rings (one benzene ring and one oxygen-containing ring).

Explanation

The presence of a bromoethyl group at the 6th position of the benzodioxin ring introduces a bromine atom and an ethyl group, which can influence the compound's chemical and biological properties.

Explanation

Due to its unique structure, the compound may be used as a building block or intermediate in the synthesis of various organic compounds, including those with potential pharmaceutical or industrial applications.

Explanation

The parent compound, 1,4-benzodioxin, is known to be present in various plants, which may suggest that this derivative could also be found in nature or have potential applications in the study of plant biochemistry.

Bicyclic organic compound

1,4-Benzodioxin

Bromoethyl group

6-(2-bromoethyl)

Potential applications

Organic synthesis, medicinal chemistry, and starting material for other organic compounds

Pharmacological and toxicological effects

Not extensively studied

Presence in plants

Commonly found in various plants

Upstream product

• 127264-09-9 1′-(dihydro-3,4-benzodioxinyl)ethan-2′-ol 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 67200-27-5 6-vinyl-2,3-dihydrobenzo[b][1,4]dioxine 
• 4629-54-3 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone 

Relevant academic research and scientific papers

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

IDO inhibitors

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes.The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.